Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 468 participants.
Also called NCT07374718
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 468 participants
- Registry
-
NCT07374718
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07374718. Randomized; no masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
- Condition
- Acute Coronary Syndrome (ACS)
- Condition
- High Bleeding Risk(HBR)
- Intervention (Device)
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy
- Intervention (Device)
- Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Lead sponsor
- Shenyang Northern Hospital
- Collaborator
- Chinese Academy of Medical Sciences, Fuwai Hospital
Record details
- Record id
cardio:ct-nct07374718- Content hash
a89884a87c42cb3f33d7e88c95bc21376a66b4693c23513da98a0f5ebc4e5bd8